Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition

Conley, R. B., Adib, G., Adler, R. A., Akesson, K. E., Alexander, I. M., Amenta, K. C., et al. Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. Journal of Bone and Mineral Research, September 2019. https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.3877

Core Outcome Set-STAndardised Protocol Items: The COS-STAP Statement

Kirkham J.J., Gorst S, Altman D.G., Blazeby J.M., Clarke M, Tunis, S, Williamson P.R. Core Outcome Set-STAndardised Protocol Items: The COS-STAP Statement. Trials 2019; 20:116.

Practical Guidance for Involving Stakeholders in Health Research (December 2018)

Concannon, T.W., Grant, S, Welch, V, Petkovic, J, Selby, J, Crowe, S, Synnot, A, Greer-Smith, R, Mayo-Wilson, E, Tambor, E, Tugwell, P. Practical Guidance for Involving Stakeholders in Health Research. Journal of General Internal Medicine, 2018,1-6. https://doi.org/10.1007/s11606-018-4738-6

Designing Late Phase Clinical Trials of Disease-modifying Agents to Delay or Prevent Dementia due to Alzheimer 's Disease

This document reports on a project conducted by the Center for Medical Technology Policy 's Green Park Collaborative to create multi-stakeholder vetted recommendations for the design of studies in later phases of drug development to evaluate the ability of disease-modifying agents to delay or prevent the onset of dementia due to Alzheimer 's disease.

Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project

Iorio A, Skinner MW, Clearfield E, Messner D, Pierce GF, Witkop M, Tunis S; for the coreHEM panel. Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project. Haemophilia. 2018;00:1 '6. https://doi.org/10.1111/hae.13504

Insurance Coverage for Genomic Tests

Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP Jr, Douglas MP, Weldon CB. Insurance coverage for genomic tests. Science 2018 April 20. 360(6386):278-279. doi: 10.1126/science.aas9268. Epub 2018 Apr 19. PMID: 29674586

Paying for Cures: Perspectives on Solutions to the 'Affordability Issue '

Karlsberg Schaffer S, Messner D, Mestre-Ferrandiz J, Tambor E, Towse A. Paying for Cures: Perspectives on Solutions to the 'Affordability Issue. ' Value in Health 2018; 21: 276-279.

Choosing Important Health Outcomes for Comparative Effectiveness Research: An updated systematic review and involvement of low and middle income countries.

Davis K, Gorst SL, Harman N, Smith V, Gargon E, Altman DG, Blazeby JM, Clarke M, Tunis S, Williamson PR. Choosing important health outcomes for comparative effectiveness research: an updated systematic review and involvement of low and middle-income countries. PONE-D-17-33253R1. PLoS One. 2018 Feb 13;13(2):e0190695. doi: 10.1371/journal.pone.0190695. eCollection 2018. PMID: 29438429 PMCID: PMC5810981 DOI: 10.1371/journal.pone.0190695

Stakeholder Perspectives Regarding Alternate Approaches to Informed Consent for CER

Morain S, Tambor E, Moloney R, Kass N, Tunis S, Hallez K, Faden R. Stakeholder perspectives regarding alternative approaches to informed consent for comparative effectiveness research. Learn Health Sys 2017;e10047. doi: 10.1002/lrh2.10047

Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-Stakeholder Consensus

Conley RB, ', Al Naber J, Messner, DA, et al. Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-Stakeholder Consensus. Cell 2017;171(5):982-986. doi.org/10.1016/j.cell.2017.10.032

Core Outcome Set-STAndards for Development: The COS-STAD recommendations

Kirkham JJ, Davis K, Altman DG, Blazeby JM, Clarke M, Tunis S, Williamson PR. Core Outcome Set-STAndards for Development: The COS-STAD recommendations. PLoS Med 2017;14(11):e1002447. doi: 10.1371/journal.pmed.1002447. eCollection. PMID: 29145404

Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains.

Lipman PD, Loudon K, Moloney R, Messner D, Stoney CM. Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains. Trials 2017;18(1):532. doi. 10.1186/s13063-017-2267-y. PMID: 29126437

Evaluating the comparative effectiveness of treatment sequences in oncology: a new approach

Messner DA, Towse A, Mohr PE, Garau M. The future of comparative effectiveness and relative efficacy of drugs: an international perspective. J Comp Eff Res. 2015;4(4):419-27. doi:10.2217/CER.15.6. PMID: 25730094. ISSN: 2042-6305.

Payer perspective on future acceptability of comparative effectiveness and relative effectiveness research (2015)

Moloney R, Mohr P, Hawe E, Shah K, Garau M, Towse A. Payer perspective on future acceptability of comparative effectiveness and relative effectiveness research. Int. J. Technol. Assess. Health Care. 2015;31(1-2):90-98. doi:10.1017/S0266462315000203. PMID: 26168804

Medical and pharmacy coverage decision making at the population level (2014)

Mohr PE, Tunis SR. Medical and pharmacy coverage decision making at the population level. J. Manag Care Pharm. 2014;20(6):547-554. PMID: 24856592

Understanding the role and evidence expectations of health technology assessment and coverage/payer bodies: What are they looking for, and how and why does this differ from what regulators require? (2014)

Henshall C, Sanson L, Eichler H-G, Lemgruber A, Longson C, O 'Rourke B, Tunis S. Understanding the role and evidence expectations of health technology assessment and coverage/payer bodies: What are they looking for, and how and why does this differ from what regulators require? Therapeutic Innovation & Regulatory Science. 2014;48(3):341-46. doi:10.1177/2168479013512488.

The views of quality improvement professionals and comparative effectiveness researchers on ethics, IRBs, and oversight (2015)

Whicher D, Kass N, Saghai Y, Faden R, Tunis S, Pronovost P. The views of quality improvement professionals and comparative effectiveness researchers on ethics, IRBs, and oversight. J Empir Res Hum Res Ethics. 2015;10(2):132-44. doi:10.1177/1556264615571558

Futurescapes: Evidence expectations in Europe for comparative effectiveness research for drugs in 2020 (2015)

Towse A, Garau M, Mohr P, Messner DA. Futurescapes: Evidence expectations in Europe for comparative effectiveness research for drugs in 2020. J Comp Eff Res. 2015;4(4):401-18. doi:10.2217/CER.15.7. PMID: 25740283. ISSN: 2042-6305.

Futurescapes: Evidence expectations in the USA for comparative effectiveness research for drugs in 2020 (2015)

Messner DA, Mohr PE, Towse A. Futurescapes: Evidence expectations in the USA for comparative effectiveness research for drugs in 2020. J Comp Eff Res. 2015;4(4):385-400. doi:10.2217/CER.15.6. PMID: 25730709. ISSN: 2042-6305.

The future of comparative effectiveness and relative efficacy of drugs: an international perspective (2015)

Messner DA, Towse A, Mohr PE, Garau M. The future of comparative effectiveness and relative efficacy of drugs: an international perspective. J Comp Eff Res. 2015;4(4):419-27. doi:10.2217/CER.15.6. PMID: 25730094. ISSN: 2042-6305.

From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients (2015)

Eichler H-G, Baird LG, Barker R, ' Tunis SR, et al. From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin Pharmacol Ther. 2015;97(3):234-46. doi:10.1002/cpt.59. PMID: 25669457

Reimbursing NGS Testing. Clinical OMICs ' Molecular diagnostics in personalized medicine (2015)

Tunis S. Reimbursing NGS Testing. Clinical OMICs ' Molecular diagnostics in personalized medicine. online digital publication (http://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss1/#/20). 2015;2(1):21-23.

What can comparative effectiveness research contribute to integrative health in international perspective? (2014)

Witt C, Withers SR, Grant S, Lauer M, Tunis SR, Berman B. What can comparative effectiveness research contribute to integrative health in international perspective? J Altern Complement Med. 2014;20(11):874-80. doi: 10.1089/acm.2014.0073. PMID: 25372702. PMCID: PMC4238246

Accelerated access to innovative medicines for patients in need (2014)

Baird LG, Banken R, Eichler H-G, Kristensen FB, Lee DK, Lim JCW, Lim R, Longson C, Pezalla E, Salmonson T, Samaha D, Tunis S, Woodcock J, Hirsch G. Accelerated access to innovative medicines for patients in need. Clin Pharmacol Ther. 2014;96(5):559-71. doi: 10.1038/clpt.2014.145. PMID: 25006877

Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes? (Oct 2013)

Calonge N, Klein RD, Berg JS, et al. Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes? Genet Med. 2013; doi: 10.1038/gim.2013.141. PMID: 24071797.

Methodological recommendations for comparative research on the treatment of chronic wounds.

Sonnad SS, Goldsack JC, Mohr P, Tunis S. J Wound Care. 2013 Sep;22(9):470-80. PMID: 24005781

Medicare Policy on Bariatric Surgery: Decision Making in the Face of Uncertainty (Sept 2013)

Tunis SR, Messner DA. Medicare policy on bariatric surgery: decision making in the face of uncertainty. J Amer Med Assoc. 2013: doi:10.1001/jama.2013.278849

Recommendations for the Design of Phase 3 Pharmaceutical Trials that are more Informative for Patients, Clinicians, and Payers (Sept 2013)

Sonnad SS, Mullins CD, Whicher D, Goldsak J, Mohr PE, Tunis SR. Contem Clin Trials. 2013:pii:S1157-7144(13):132-138

Ethics and Informed Consent for Comparative Effectiveness Research with Prospective Electronic Clinical Data (August 2013)

Faden RR, Kass, NE, Whicher DM, Stewart W, Tunis SR. Med Care. 2013;51(8 Suppl 3):S53-7. doi: 10.1097/MLR.0b013e31829b1e4b. PMID: 23793051

Break a Vicious Cycle (July 2013)

Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DGB, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR. Sci Transl Med. 2013:5(196):196cm6. doi:10.1126scitranslmed.3005950

Encouraging Value-based Insurance Designs in State Health Insurance Exchanges (July 2013)

Buttorff CA, Tunis SR, Weiner JP. Am J Manag Care. 2013;19(7):593-600. PMID: 23919422

Performance-based Risk-sharing Arrangements 'Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-based Risk-sharing Arrangements Task Force. (July 2013)

Garrison LP, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, Severens JL, Siviero P, Sleeper M. Value in Health. 2013;16(5):703-719. doi:10.1016/j.jval.2013.04.011

Value-of-Information Analysis Within a Stakeholder-driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics (April 2013)

Carlson JJ, ..., Esmail LC, Deverka PA, et al. Med Decis Making. 2013;33(4):463-471. doi: 10.1177/0272989X13484388. PMID: 23635833

Regulatory and Reimbursement Innovation (March 2013)

Lindor RA, Allocco SJ, Cheatham L, et al. Sci. Transl. Med. 2013;5(176):176cm3. doi: 10.1126/scitranslmed.3005437

Recommendations From the EGAPP Working Group: Does Genomic Profiling to Assess Type 2 Diabetes Risk Improve Health Outcomes? (March 2014)

Evaluation of Genomic Applications in Practice Prevention Working Group. Genet Med. 2013:15(8):612-617. doi:10.1038/gim.2013.9

Recommendations from the EGAPP Working Group: Can Testing of Tumor Tissue for Mutations in EGFR Pathway Downstream Effector Genes in Patients with Metastatic Colorectal Cancer Improve Health Outcomes by Guiding Decisions Regarding anti-EGFR Therapy? (Feb 2013)

Calonge N, Fisher NL, Berg AO, et al. Genet Med. 2013; doi: 10.1038/gim.2012.184. PMID: 23429431.

Getting Our Priorities Straight: a Novel Framework for Stakeholder-informed Prioritization of Cancer Genomics Research (Feb 2013)

Esmail LC, Roth J, Deverka PA. Genet Med. 2013;15(2):115-122. doi: 10.1039/gim.2012.103. PMID: 23037935

Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update (January 2013)

Veenstra DL, Piper M, Tunis SR et al. Genet Med. 2013;15(1):14-24. doi: 10.1038/gim.2012.106. PMID: 22955111

An Ethics Framework for a Learning Health Care System: A Departure from Traditional Research Ethics and Clinical Ethics (January 2013)

Faden RR, Kass NE, Goodman SN, Pronovost P, Tunis SR, Beauchamp TL. Hastings Center Report. 2013:43(s1):S16-S27. doi: 10.1002/hast.134

The Research-treatment Distinction: A Problematic Approach for Determining Which Activities Should have Ethical Oversight (January 2013)

Kass NE, Faden RR, Goodman SN, Pronovost P, Tunis SR, Beauchamp TL. Hastings Center Report. 2013;43(s1):S4-S15. doi: 10.1002/hast.133

Stakeholder Participation in Comparative Effectiveness Research: Defining a Framework for Effective Engagement (December 2012)

Deverka PA, Lavallee DM, Desai PJ, Esmail LC, Ramsey SD, Veenstra DL, Tunis SR. J Comp Eff Res. 2012;1(2):181 '194. PMID: 22707880. PMCID: PMC3371639

Incorporating Stakeholder Perspectives in Developing a Translation Table Framework for Comparative Effectiveness Research (December 2012)

Gliklich RE, Tunis SR, Mohr PE, Messner DA, Moloney RM, Karkare SU, et al. J Comp Eff Res. 2012; 1(3), 281-292. doi: 10.2217/cer.12.25.

Stakeholder Assessment of the Evidence for Cancer Genomic Tests: Insights from Three Case Studies (December 2012)

Deverka PA, Schully SD, Ishibe N, et al. Genet Med. 2012;14(7):656-662. doi: 10.1038/gim.2012.3. PMID:22481130

Recommendations for Incorporating Patient-reported Outcomes into Clinical Comparative Effectiveness Research in Adult Oncology (December 2012)

Basch E, ' Spencer MR, Tunis SR, et al. J Clin Oncol. 2012;30(34);4249-4255. doi: 10.1200/JCO.2012.42.5967. PMID:23071244

Improving the Efficiency and Effectiveness of Pragmatic Clinical Trials in Older Adults in the United States.

Saag KG, Mohr PE, Esmail L, Wright N, Curtis JR, Cutter G, Delzell E, Gary LC, Lewis CE, Harrington TM, Karkare SU, Kilgore ML, Moloney R, Mudano AS, Oliveira A, Singh J, Warriner A, Zhang J, Berger M, Cummings SR, Pace W, Solomon DH, Wallace R, Tunis SR. Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States. Contemp Clin Trials. 2012;33(6)1211-1216. doi: 10.1016/j.cct.2012.07.002. PMID: 22796098

Effectiveness Guidance Document (EGD) for Acupuncture Research - a Consensus Document for Conducting Trials (Sept 2012)

Witt CM, Aickin M, Tunis SR, et al. BMC Complement Altern Med. 2012;12(1):148. doi 10.1189/1472-6882-12-148. PMID: 22953730

Stakeholder Engagement in Comparative Effectiveness Research: How Will We Measure Success? (Sept 2012)

Lavallee DC, Williams CJ, Deverka PD, Tambor ES. Stakeholder engagement in comparative effectiveness research: how will we measure success? J Comp Eff Res. 2012;1(5):397-407. doi: 10.2217/CER.12.44

Improving Comparative Effectiveness Research: New Methodological Standards Focus on Quality and Relevance of Research to Patients (August 2012)

Tunis SR. BMJ. 2012;345:e5160. doi: 10.1136/bmj.e5160.

The Role for Pragmatic Randomized Controlled Trials (pRCTs) in Comparative Effectiveness Research (July 2012)

Chalkidou K, Tunis SR, Whicher DM, Fowler R, Zwarenstein M. Clin Trials. 2012;9(4):436-446. doi: 10.1177/1740774512450097. PMID: 22752634

Building the Evidence Base for Decision Making in Cancer Genomic Medicine Using Comparative Effectiveness Research (July 2012)

Goddard KA, Knaus WA, Tunis SR, et al. Genet Med. 2012;14(7):633-642. doi: 10.1038/gim.2012.16. PMID: 22516979

Percutaneous Vertebroplasty and Kyphopalsty for Pathologic Vertabral Fractures in the Medicare Population: Safer and Less Expensive than Open Surgery (June 2012)

Itagaki MW, Telenfield AD, Kwam, SW, Brunner JWM, Mortell KE, Brunner MC. J. Vasc Interv Radiol. 2012;23(11):1423-1429. doi: 10.1016/j.vir.2012.08.010. PMID: 23101914

Incorporating Stakeholder Perspectives In Developing a Translation Table Framework for Comparative Effectiveness Research (May 2012)

Gliklich RE, Tunis SR, Mohr PE, Messner DA, Moloney RM, Karkare SU, et al. . J Comp Eff Res. 2012; 1(3), 281-292. doi: 10.2217/cer.12.25.

Prioritization in Comparative Effectiveness Research: the CANCERGEN Experience (May 2012)

Thariani R, Wong W, Carlson JJ, Garrison L, Deverka PA, Esmail LC, et al. Med Care. 2012;50(5):388-393. doi: 10.1097/MLR.0b013e3182422a3b. PMID: 22274803. PMCID: PMC3469160

Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making (May 2012)

Brixner D, Oderda G, Mohr PE, Dubois R, Cannon E. J Manag Care Pharm. 2012;18(4-a):s01-s17

Continuous Patient Engagement in Comparative Effectiveness Research (April 2012)

Mullins CD, Abdulhalim AM, Lavallee DC. JAMA. 2012;307(15):1587-1588. doi: 10.1001/jama.2012.442. PMID: 22522684

Addressing Low-risk Comparative Effectiveness Research in Proposed Changes to US Federal Regulations Governing Research (April 2012)

Kass N, Faden R, Tunis SR. JAMA. 2012;307(15):1589-1590. doi: 10.1001/jama.2012.491. PMID: 22511685

International Collaboration in the Use of Registries for New Devices and Procedures (April 2012)

Campbell B, Patrick H; REGISTER GROUP ' Tunis SR. Br J Surg. 2012;99(6):744-745. doi: 10.1002/bjs.8791. PMID: 22508386

Looking at Comparative Effectiveness Research from Medicare 's Perspective (April 2012)

Mohr PE. J Manag Care Pharm. 2012;18(4sa): S5- S8. PMID: 22578211

Current and Future State of FDA-CMS Parallel Reviews (March 2012)

Messner, DA, Tunis, SR. Clin Pharmacol Ther. 2012;91(3), 383-385. doi: 10.1038/clpt.2011.350. PMID: 22343814

How Well Do Randomized Trials Inform Decision Making: Systematic Review Using Comparative Effectiveness Research Measures on Acupuncture for Back Pain? (Feb 2012)

Witt CM, Manheimer E, Tunis SR, et al. PLoS ONE. 2012;7(2):e32399. doi: 10.1371/journal.pone.0032399

Recommendations for Clinical Trials of Off-label Drugs Used to Treat Advanced-stage Cancer (Feb 2012)

Mullins CD, Montgomery R, Tunis SR, et al. J Clin Oncol. 2012;30(6):661-666. doi: 10.1200/JCO.2011.35.5198. PMID: 22253467

Panel Discussion (Feb 2012)

Schwartz S, Lauer M, Tunis SR, et al. 1. Clin Trials. 2012;9(1):13-21. doi: 10.1177/1740774511433047. PMID: 22334464

Comparative Performance of Two Methods that Assess the Quality of International Normalized Ratio Measures (Feb 2012)

Shermock KM, Tandon S, Srgen PJ, Lavallee DC, Clarke W, Streiff MB. Clin Biochem. 2012;45(7-8):530-534. doi: 10.1016/j.clinbiochem.2012.01.032. PMID: 22342920

Making Informed Decisions: Assessing the Strengths and Weaknesses of Study Designs and Analytic Methods for Comparative Effectiveness Research: A Briefing Document for Stakeholders (Feb 2012)

Using Health Technology Assessment to Identify Gaps in Evidence and Inform Study Design for Comparative Effectiveness Research (January 2012)

Tunis SR, Turkelson CM. J Clin Oncol. 2012;30(34):4256-4261. doi: 10.1200/JCO2012.42.6338. PMID: 23071248

A Translation Table for Patient-centered Comparative Effectiveness Research ' Guidance to Improve the Value of Research for Clinical and Health Policy Decision Making (January 2012)

Tunis SR, Messner DA, Mohr PE, Gliklich RE, and Dubois RW. J Comp Eff Res. 2012;1(3), 259-262. doi: 10.2217/cer.12.22.

A Framework for Pharmaceutical Value-based Innovation (January 2012)

Salimi T, Lehner JP, Epstein RS, Tunis SR. J Comp Eff Res. 2012; 1(1s):3-7. doi: 10.2217/cer.11.2

Facilitating CER in Cancer Genomics: Evaluating Stakeholder Perceptions of the Engagement Process (January 2012)

Deverka PA, Lavallee DC, Desai PJ, et al. J Comp Eff Res. 2012;1(4):359-370. doi: 10.2217/cer.12.36

Redesigning Radiotherapy Quality Assurance: Opportunities to Develop an Efficient, Evidence-based System to Support Clinical Trials-Report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. (January 2012)

Bekelman JE, Deye JA, Vikram B, Tunis SR, et al. Int J Radiat Oncol Biol Phys. 2012;83(3):782-790. doi: 10.1016/j.ijrobp.2011.12.080. PMID: 22425219. PMCID: PMC3361528

How Comparative Effectiveness Research Can Help Advance 'Personalized Medicine ' in Cancer Treatment (December 2011)

Ramsey SD, Veenstra D, Tunis SR, Garrison L, Crowley JJ, Baker LH. Health Aff. 2011;30(12):2259-2268. doi: 10.377/hlthaff.2010.0637. PMID: 22147853. PMCID: PMC3477796

Improving the Quality and Efficiency of the Medicare Program Through Coverage Policy: Timely Analysis of Immediate Health Policy Issues (August 2011)

Tunis SR, Berenson RA, Phurrough SE, Mohr PE. Urban Institute 2011: http://www.urban.org/url.cfm?ID=412392

A CTSA Agenda to Advance Methods for Comparative Effectiveness Research. (January 2011)

Helfand M, Tunis SR, Whitlock EP, et al. Clin Transl Sci. 2011;4(3):188-198. doi: 10.1111/j.1752-8062.2011.00282.x. PMID: 21707950

CER: Who Will Do the Studies? (November 2010)

Giffin RB, Woodcock J. CER: Who will do the studies? Health Aff. 2010;29(11):2075-2081. doi: 10.1377/hlthaff.2010.0669. PMID: 21041751

A Policy Approach to the Development of Molecular Diagnostic Tests (November 2010)

Schulman KA, Tunis SR. Nat Biotechnol. 2010;28(11):1157-1159. doi: 10.1038/nbt1110-1157. PMID: 21057480

Why Observational Studies Should Be Among the Tools Used in Comparative Effectiveness Research (October 2010)

Dreyer NA, Tunis SR, Berger M et al. Health Aff. 2010;29(10): 1818-1825. doi: 10.1377/hlthaff.2010.0666. PMID: 20921481

How Best to Engage Patients, Doctors, and Other Stakeholders in Designing Comparative Effectiveness Studies (October 2010)

Hoffman A, Montgomery R, Aubry WM, Tunis SR. Health Aff(Millwood). 2010; 29(10):1834-1841. doi: 10.1377/hlthaff.2010.0675. PMID: 20921483

US Moves to Improve Health Decisions (August 2010)

Tunis SR, Pearson SD. BMJ. 2010;341:c3615. doi: 10.1136/bmj.c3615. PMID: 20732966

A Pragmatic Explanatory Continuum Indicator Summary (PRECIS) Was Useful for Refining a Randomized Trial Design: Experiences from an Investigative Team (March 2010)

D.L. Riddle et al. / Journal of Clinical Epidemiology 63 (2010) 1271e1275

Medicare and Medical Technology 'the Growing Demand for Relevant Outcomes (Feb 2010)

Neumann PJ, Tunis SR. N Engl J Med. 2010;362(5):377-379. doi: 10.1056/NEJMp0912062. PMID: 20089955

Response to Comments on 'Comparative Effectiveness Research (January 2010)

Tunis SR, Benner J, McClellan M. Stat Med. 2010;29(19):1996-1997. doi: 10.1002/sim.4019. PMID: 20564311

How the Institute of Medicine (IOM) Report on Comparative Effectiveness Research Will Impact Imaging Research and Practice (January 2010)

Seidenfeld J, Aubry WM. Imaging Med. 2010:2(3):357-361. doi: 10.2217/iim.10.22

Generating Evidence for CER Using Pragmatic Randomized Clinical Trials (January 2010)

Mullins CD, Whicher DM, Reese ES, Tunis SR. Pharmacoeconomics. 2012; 28(10):969-976. doi: 10.2165/11536160. PMID: 20831305

Uncertainty in assessing value of oncology treatments

Mullins CD, Montgomery R, Tunis SR. Oncologist. 2010; 15(s1):58-64. doi: 10.1634/theoncologist.2010-S1-58. PMID: 20237219

Access with Evidence Development: The US Experience (January 2010)

Mohr PE, Tunis SR. Pharmacoeconomics. 2010:28(2):153-162. doi: 10.2165/11531050. PMID: 20085391

Evidence Making: Developing Tools and Strategies for Comparative Effectiveness (November 2009)

Tunis SR, Seidenfeld J. Asian Hospital & Healthcare Management. 2009;19:11-16

Comparative Effectiveness Research: Policy Context, Methods Development and Research Infrastructure (October 2009)

Tunis SR, Benner J, McClellan M. Stat Med. 2010;29(19):1963-1976. doi: 10.1002/sim.3818

Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: the Need for Transformational Change (June 2009)

Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis SR, Whicher DM, Schwartz JS. Ann Intern Med. 2009;151(3):206-209. PMID: 1957619

Does Comparative Effectiveness Research Threaten Personalized Medicine? (May 2009)

Garber AM, Tunis SR. N Engl J Med. 2009;360(19):1925-1927. doi: 10.1056/NEJMp0901355. PMID: 19420360

The National Oncologic PET Registry: Lessons Learned for Coverage with Evidence Development (May 2009)

Tunis SR, Whicher DM. J Am Coll Radiol. 2009;6(5):360-365. doi: 10.1016/j.acr.2009.10.016. PMID: 19394577

PRECIS: The Pragmatic Explanatory Continuum Indicator Summary (April 2009)

Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis SR, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): A tool to help trial designers. CMAJ. 2009;180(10):E47-57. doi: 10.1503/cmaj.090523. PMID: 19372436

Comparative Effectiveness Research in Ontario, Canada: Producing Relevant and Timely Information for Health Care Decisions (January 2009)

Whicher DM, Chalkidou K, Dhalla IA, Levin L, Tunis SR. Milbank Q. 2009;87:585-606. doi: 10.1111/j.1468-0009.209.00572.x. PMID: 19751283. PMCID: PMC2881460

Comparative Effectiveness Research Priorities: Identifying Critical Gaps in Evidence for Clinical and Health Policy Decision Making (January 2009)

Chalkidou K, Whicher DM, Kary W, Tunis SR. Int J Technol Assess Health Care. 2009;25(3):241-248. doi: 10.107-S0266462309990225. PMID: 1961934

Comparative Effectiveness Research and Evidence-Based Health Policy: Experience from Four Countries (January 2009)

Chalkidou K, Tunis SR, Lopert R, et al. Milbank Q. 2009;87(2):339-367. doi: 10.1111/j.1468-0009.2006.00560.x. PMID: 19523121

Improving the Reporting of Pragmatic Trials: An Extension of the CONSORT Statement (Dec 2008)

Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis SR. BMJ. 2008;337:a2390. doi: 10.1136/bmj.a2390. PMID: 19001484. PMCID: PMC3266844

Challenges in Australian Policy Processes for Disinvestment from Existing, Ineffective Health Care Practices. (October 2007)

Elshaug AG, Hiller JE, Tunis SR, Moss JR. Aust New Zealand Health Policy. 2007;4:23. doi: 10.1186/17438462-4-23. PMCID: PMC2174492

Reflections on Science, Judgment, and Value in Evidence-Based Decision Making: A Conversation with David Eddy. (June 2007)

Tunis SR. Health Aff. 2007;26(4):w500-w515. doi: 10.1977/hlthaff.26.4.w500. PMID: 17580317

Federal Initiatives to Support Rapid Learning About New Technologies (January 2007)

Tunis SR, Carino TV, Williams RD 2nd, Bach PB. Health Aff (Millwood). 2007;26(2):w140-149. doi: 10.1377/hlthaff.26.2.w140. PMID: 17259196